Creabilis

Creabilis is an emerging European specialty pharmaceutical company focused on dermatology. Creabilis has an outstanding track record in dermatology research and leverages this experience to create a rich pipeline of clinical and preclinical candidates, which the company will promote directly or through partnerships. The most advanced product is CT327, for the treatment of psoriasis. CT327 will enter Phase II clinical trials in 2009. Creabilis' pipeline also includes several preclinical candidates derived from its groundbreaking drug discovery programs.